Procter & Gamble Health
Market cap ₹9,138 Cr
- P/E
- 26.26
- Day range
- ₹5,360.50 – ₹5,543.50
- 52-week range
- ₹4,707.00 – ₹6,975.00
- Volume
- 21,566
- Open
- ₹5,501.50
- Prev close
- ₹5,464.50
Latest results · Q2 FY27(standalone)Revenue ₹382 Cr+17.7%Profit ₹112 Cr+25.9%Margin 29.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
PGHL in NSE indices and F&O
Research profile
Composite 76 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.8%
- 12-1 mom.
- -12.5%
- Return / vol
- -0.28
- Magic Formula
- #41
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Procter & Gamble HealthPGHL | ₹9,138 Cr | 26.26 | — | 61.6% | 84.0% | 40.0% | 0.01 | +17.5% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2h agoHeadlines about Procter & Gamble Health from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- ROE (FY26)
- 61.6%
- ROCE (latest year)
- 84%
Moving averages (NSE)
- 20-day
- ₹5,524.98
- Price below
- 50-day
- ₹5,444.37
- Price above
- 200-day
- ₹5,592.34
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 | 382 |
| YoY Sales growth | — | -21 | -6 | — | 0 | — | — | — | — | — | — | — |
| Expenses | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 | 230 |
| Operating Profit | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 | 152 |
| OPM % | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% | 40% |
| Other Income | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | 6 |
| Profit before tax | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 | 150 |
| Tax % | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% | 26% |
| Net Profit | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 | 112 |
| EPS in Rs | ₹43.42 | ₹28.05 | ₹10.11 | ₹49.60 | ₹54.76 | ₹36.86 | ₹39.87 | ₹53.34 | ₹46.74 | ₹56.99 | ₹57.92 | ₹67.18 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+21 days since Jun 2021 (S)
-1 days since Jun 2021 (S)
-17 days since Jun 2021 (S)
+36 days since Jun 2021 (S)
+23 days since Jun 2021 (S)
Strengths, risks & growth
Procter & Gamble Health Ltd, formerly Merck Ltd, manufactures and markets vitamins, minerals, supplements and other healthcare products under brands including Neurobion, Livogen, Seven Seas, Evion, Polybion and Nasivion. It is part of the US-based P&G Group and operates a plant at Usgaon, Goa [1]
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 51.82% | 51.82% | 51.82% | 51.82% | 0.00 pp |
| FII | 6.97% | 6.20% | 6.33% | 6.43% | +0.10 pp |
| DII | 13.84% | 13.67% | 12.44% | 12.63% | +0.19 pp |
| Public | 27.37% | 28.30% | 29.41% | 29.13% | -0.28 pp |
Filed with NSE for Sept 2026: promoters 51.82%, public 48.18%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 8.89% (-0.16 pp)- Promoters51.8%
- Foreign institutions6.4%
- Mutual funds8.9%
- Insurance3.6%
- Other domestic institutions0.1%
- Retail21.5%
- Others7.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Nippon India Small Cap Fund | 4.34% | 0.51% | -0.07 pp |
| UTI MNC Fund | 1.19% | 4.25% | -0.29 pp |
| DSP Healthcare Fund | 1.00% | 2.42% | -0.47 pp |
| Aditya Birla SL MNC Fund | 0.59% | 1.87% | -0.03 pp |
| Tata India Pharma & Healthcare Fund | 0.52% | 3.15% | +0.73 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 26.1%
- Downside volatility
- 24.7%
- Worst 5% of days
- 2.4%
- Average of that tail
- 3.5%
- Max drawdown (1Y)
- 27.5%
- Below its peak
- 20.4%
Against the market
- Beta vs Nifty 50
- 0.47
- Correlation
- 0.25
- Relative strength (3M)
- -9.6%
- ATR (14)
- 3.7%
Return
- Return 1M
- +5.9%
- Return 3M
- -5.7%
- Return 6M
- +4.8%
- Return 1Y
- -7.3%
- vs 200-day average
- -1.6%
Momentum
- RSI (14)
- 48.6
- MACD histogram
- -9.64
- Stochastic %K
- 21.4
- ADX (14)
- 28.2
- +DI / −DI
- 25.1 / 22.0
- Money flow index
- 62.2
Participation
- Delivery (20d avg)
- 52.9%
- vs its 60-day baseline
- -1.9 pts
- Volume vs 20-day
- +0.4σ
- Close vs day's VWAP
- +1.4%
- 52-week position
- 34 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Corporate actions
- dividend₹45.00
Dividend - Rs 45 Per Share
27 Aug 2026ex-date - dividend₹110.00
Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share
12 Feb 2026ex-date - dividend₹45.00
Dividend - Rs 45 Per Share
22 Aug 2025ex-date - dividend₹80.00
Interim Dividend - Rs 80 Per Share
21 Feb 2025ex-date - dividend₹60.00
Annual General Meeting/Dividend - Rs 60 Per Share
28 Nov 2024ex-date - dividend₹50.00
Interim Dividend - Rs 50 Per Share & Special Dividend Rs 150 Per Share
14 Feb 2024ex-date - dividend₹50.00
Annual General Meeting/Dividend - Rs 50 Per Share
23 Nov 2023ex-date - dividend₹45.00
Interim Dividend - Rs 45 Per Share
13 Feb 2023ex-date - dividend₹11.50
Annual General Meeting/Dividend - Rs 11.50 Per Share
15 Nov 2022ex-date - dividend₹41.00
Interim Dividend - Rs 41 Per Share
12 May 2022ex-date - dividend₹40.00
Annual General Meeting/Dividend - Rs 40 Per Share/Special Dividend - Rs 90 Per Share
2 Nov 2021ex-date - dividend₹42.00
Annual General Meeting/Dividend - Rs 42 Per Share Special Dividend - Rs 188 Per Share
18 Nov 2020ex-date - dividend₹416.00
Annual General Meeting / Special Dividend - Rs 416 Per Share/ Final Dividend - Rs 24 Per Share
23 May 2019ex-date - dividend₹15.00
Annual General Meeting/ Dividend - Rs 15 Per Share
21 May 2018ex-date - dividend₹11.00
Annual General Meeting/Dividend-Rs 11/- Per Share (Revised)
25 May 2017ex-date - dividend₹7.50
Annual General Meeting/Dividend - Rs 7.50/- Per Share (Book Closure Dates Revised)
22 Apr 2016ex-date - dividend₹6.00
Annual General Meeting / Dividend - Rs 6/- Per Share
30 Mar 2015ex-date - dividend₹8.50
Annual General Meeting/Dividend - Rs 8.50/- Per Share
10 Mar 2014ex-date - dividend₹2.50
Annual General Meeting/Dividend Rs 2.50 Per Share
7 Mar 2013ex-date - otherNot available — not reported in this filing
Annual General Meeting
27 Mar 2012ex-date
Company announcements
Please find attached signed Certifiacte for confirming compliance under Regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended September 30, 2026.
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited financial ....
We would like to inform you that the Trading Window of the Company shall remain closed for the Directors and Designated Employees from October 1, 2026 until 48 hours from the publication ....
Stock Exchange is informed about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization.
The shareholders at their AGM held on September 3, 2026 approved the re-appointment of Mr. S. Madhavan as Independent Director of the Company for a period of 5 years effective November 15, 2026.
Scrutinizers Report and E-Voting results for the Annual General Meeting held on September 3, 2026.
Enclosed a summary of proceedings of the Annual General Meeting held today, viz., September 3, 2026.
The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.
The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.
Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.
Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.
Record Date for Purpose of Dividend
Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.
Unaudited Financial Results for the Quarter ended June 30, 2026
Outcome of Board Meeting.
Filed with BSE (scrip 500126); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Sep 2026Slides
- Jun 2026Transcript
- Jun 2025TranscriptSlides
- Dec 2023Slides
- Nov 2022Slides
- May 2018Slides
Credit ratings
- Rating update · 27 Jun 2019 from icra
- Rating update · 25 Apr 2018 from icra
- Rating update · 26 Feb 2018 from icra
- Rating update · 31 Dec 2016 from icra
- Rating update · 22 Sep 2015 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Procter & Gamble Health: common questions
Answered from the figures on this page.